Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

What can independent research for mesothelioma achieve to treat this orphan disease?

Guazzelli A, Meysami P, Bakker E, Bonanni E, Demonacos C, Krstic-Demonacos M, Mutti L.

Expert Opin Investig Drugs. 2019 Aug;28(8):719-732. doi: 10.1080/13543784.2019.1638363. Epub 2019 Jul 1. Review.

PMID:
31262194
2.

The Biochemical Role of the Human NEIL1 and NEIL3 DNA Glycosylases on Model DNA Replication Forks.

Albelazi MS, Martin PR, Mohammed S, Mutti L, Parsons JL, Elder RH.

Genes (Basel). 2019 Apr 23;10(4). pii: E315. doi: 10.3390/genes10040315.

3.

When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?

Baird AM, Easty D, Jarzabek M, Shiels L, Soltermann A, Klebe S, Raeppel S, MacDonagh L, Wu C, Griggs K, Kirschner MB, Stanfill B, Nonaka D, Goparaju CM, Murer B, Fennell DA, O'Donnell DM, Barr MP, Mutti L, Reid G, Finn S, Cuffe S, Pass HI, Opitz I, Byrne AT, O'Byrne KJ, Gray SG.

Front Endocrinol (Lausanne). 2019 Feb 26;10:89. doi: 10.3389/fendo.2019.00089. eCollection 2019.

4.

Ultrastructure of the scolex of Orygmatobothrium schmittii (Cestoda: Phyllobothriidea).

Mutti LD, Ivanov VA.

J Morphol. 2019 Apr;280(4):494-507. doi: 10.1002/jmor.20959. Epub 2019 Feb 15.

PMID:
30768746
5.

BAP1 Status Determines the Sensitivity of Malignant Mesothelioma Cells to Gemcitabine Treatment.

Guazzelli A, Meysami P, Bakker E, Demonacos C, Giordano A, Krstic-Demonacos M, Mutti L.

Int J Mol Sci. 2019 Jan 19;20(2). pii: E429. doi: 10.3390/ijms20020429.

6.

ERS statement on harmonised standards for lung cancer registration and lung cancer services in Europe.

Rich AL, Baldwin DR, Beckett P, Berghmans T, Boyd J, Faivre-Finn C, Galateau-Salle F, Gamarra F, Grigoriu B, Hansen NG, Hardavella G, Jakobsen E, Jovanovic D, Konsoulova A, Massard G, McPhelim J, Meert AP, Milroy R, Mutti L, Paesmans M, Peake MD, Putora PM, de Ruysscher DKM, Sculier JP, Scherpereel A, Subotic DR, Van Schil P, Blum TG.

Eur Respir J. 2018 Dec 20;52(6). pii: 1800610. doi: 10.1183/13993003.00610-2018. Print 2018 Dec.

PMID:
30361252
7.

Aberrant O-glycosylation modulates aggressiveness in neuroblastoma.

Cuello HA, Segatori VI, Albertó M, Gulino CA, Aschero R, Camarero S, Mutti LG, Madauss K, Alonso DF, Lubieniecki F, Gabri MR.

Oncotarget. 2018 Sep 25;9(75):34176-34188. doi: 10.18632/oncotarget.26169. eCollection 2018 Sep 25.

8.

p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification.

Tian K, Bakker E, Hussain M, Guazzelli A, Alhebshi H, Meysami P, Demonacos C, Schwartz JM, Mutti L, Krstic-Demonacos M.

J Transl Med. 2018 Oct 13;16(1):282. doi: 10.1186/s12967-018-1650-0.

9.

A Polysome-Based microRNA Screen Identifies miR-24-3p as a Novel Promigratory miRNA in Mesothelioma.

Oliveto S, Alfieri R, Miluzio A, Scagliola A, Secli RS, Gasparini P, Grosso S, Cascione L, Mutti L, Biffo S.

Cancer Res. 2018 Oct 15;78(20):5741-5753. doi: 10.1158/0008-5472.CAN-18-0655. Epub 2018 Aug 2.

10.

Scientific Advances and New Frontiers in Mesothelioma Therapeutics.

Mutti L, Peikert T, Robinson BWS, Scherpereel A, Tsao AS, de Perrot M, Woodard GA, Jablons DM, Wiens J, Hirsch FR, Yang H, Carbone M, Thomas A, Hassan R.

J Thorac Oncol. 2018 Sep;13(9):1269-1283. doi: 10.1016/j.jtho.2018.06.011. Review.

11.

Surgery for malignant pleural mesothelioma: an international guidelines review.

Ricciardi S, Cardillo G, Zirafa CC, Carleo F, Facciolo F, Fontanini G, Mutti L, Melfi F.

J Thorac Dis. 2018 Jan;10(Suppl 2):S285-S292. doi: 10.21037/jtd.2017.10.16. Review.

12.

Insight into glucocorticoid receptor signalling through interactome model analysis.

Bakker E, Tian K, Mutti L, Demonacos C, Schwartz JM, Krstic-Demonacos M.

PLoS Comput Biol. 2017 Nov 6;13(11):e1005825. doi: 10.1371/journal.pcbi.1005825. eCollection 2017 Nov.

13.

Giant atypical lipoma.

Mascarenhas MRM, Mutti LA, Paiva JMG, Enokihara MMSES, Rosa IP, Enokihara MY.

An Bras Dermatol. 2017 Jul-Aug;92(4):546-549. doi: 10.1590/abd1806-4841.20174447.

14.

Immunotherapy advances for mesothelioma treatment.

Bakker E, Guazzelli A, Ashtiani F, Demonacos C, Krstic-Demonacos M, Mutti L.

Expert Rev Anticancer Ther. 2017 Sep;17(9):799-814. doi: 10.1080/14737140.2017.1358091. Epub 2017 Jul 31. Review.

PMID:
28724330
15.

Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma.

Guazzelli A, Bakker E, Tian K, Demonacos C, Krstic-Demonacos M, Mutti L.

Expert Opin Investig Drugs. 2017 Aug;26(8):933-944. doi: 10.1080/13543784.2017.1351545. Epub 2017 Jul 12. Review.

PMID:
28679291
16.

Correction: MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.

Melaiu O, Stebbing J, Lombardo Y, Bracci E, Uehara N, Bonotti A, Cristaudo A, Foddis R, Mutti L, Barale R, Gemignani F, Giamas G, Landi S.

PLoS One. 2017 Jun 22;12(6):e0180317. doi: 10.1371/journal.pone.0180317. eCollection 2017.

17.

Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism.

De Santi C, Melaiu O, Bonotti A, Cascione L, Di Leva G, Foddis R, Cristaudo A, Lucchi M, Mora M, Truini A, Tironi A, Murer B, Boldorini R, Cipollini M, Gemignani F, Gasparini P, Mutti L, Landi S.

Sci Rep. 2017 Jun 9;7(1):3140. doi: 10.1038/s41598-017-02694-0.

18.

Differential regulation of cell death pathways by the microenvironment correlates with chemoresistance and survival in leukaemia.

Qattan MY, Bakker EY, Rajendran R, Chen DW, Saha V, Liu J, Zeef L, Schwartz JM, Mutti L, Demonacos C, Krstic-Demonacos M.

PLoS One. 2017 Jun 5;12(6):e0178606. doi: 10.1371/journal.pone.0178606. eCollection 2017.

19.

The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.

Pattarozzi A, Carra E, Favoni RE, Würth R, Marubbi D, Filiberti RA, Mutti L, Florio T, Barbieri F, Daga A.

Stem Cell Res Ther. 2017 May 25;8(1):119. doi: 10.1186/s13287-017-0573-7.

20.

Giant congenital melanocytic nevi: 40 years of experience with the serial excision technique.

Mutti LA, Mascarenhas MRM, Paiva JMG, Golcman R, Enokihara MY, Golcman B.

An Bras Dermatol. 2017 Mar-Apr;92(2):256-259. doi: 10.1590/abd1806-4841.20174885.

21.

Inhibition of the platelet-derived growth factor receptor beta (PDGFRB) using gene silencing, crenolanib besylate, or imatinib mesylate hampers the malignant phenotype of mesothelioma cell lines.

Melaiu O, Catalano C, De Santi C, Cipollini M, Figlioli G, Pellè L, Barone E, Evangelista M, Guazzelli A, Boldrini L, Sensi E, Bonotti A, Foddis R, Cristaudo A, Mutti L, Fontanini G, Gemignani F, Landi S.

Genes Cancer. 2017 Jan;8(1-2):438-452. doi: 10.18632/genesandcancer.129.

22.
23.

Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals.

De Santi C, Pucci P, Bonotti A, Melaiu O, Cipollini M, Silvestri R, Vymetalkova V, Barone E, Paolicchi E, Corrado A, Lepori I, Dell'Anno I, Pellè L, Vodicka P, Mutti L, Foddis R, Cristaudo A, Gemignani F, Landi S.

Occup Environ Med. 2017 Jun;74(6):456-463. doi: 10.1136/oemed-2016-104024. Epub 2017 Mar 25.

PMID:
28343162
24.

Anti-CTLA-4 therapy for malignant mesothelioma.

Guazzelli A, Bakker E, Krstic-Demonacos M, Lisanti MP, Sotgia F, Mutti L.

Immunotherapy. 2017 Mar;9(3):273-280. doi: 10.2217/imt-2016-0123. Review.

PMID:
28231719
25.

Switching off malignant mesothelioma: exploiting the hypoxic microenvironment.

Nabavi N, Bennewith KL, Churg A, Wang Y, Collins CC, Mutti L.

Genes Cancer. 2016 Nov;7(11-12):340-354. doi: 10.18632/genesandcancer.124. Review.

26.

New standard for assessing asbestos exposure and its consequences?

Oliver LC, Welch L, Frank AL, Lemen RA, Mutti L.

Occup Environ Med. 2016 Oct;73(10):709-10. doi: 10.1136/oemed-2016-103693. Epub 2016 Jul 27. No abstract available.

PMID:
27466614
27.

Repurposing atovaquone: targeting mitochondrial complex III and OXPHOS to eradicate cancer stem cells.

Fiorillo M, Lamb R, Tanowitz HB, Mutti L, Krstic-Demonacos M, Cappello AR, Martinez-Outschoorn UE, Sotgia F, Lisanti MP.

Oncotarget. 2016 Jun 7;7(23):34084-99. doi: 10.18632/oncotarget.9122.

28.

A new species of Paraberrapex Jensen, 2001 (Cestoda: Lecanicephalidea) from Squatina guggenheim Marini (Squatiniformes: Squatinidae) off Argentina.

Mutti LD, Ivanov VA.

Folia Parasitol (Praha). 2016 Mar 8;63. pii: 2016.007. doi: 10.14411/fp.2016.007.

29.

Targeting hypoxic response for cancer therapy.

Paolicchi E, Gemignani F, Krstic-Demonacos M, Dedhar S, Mutti L, Landi S.

Oncotarget. 2016 Mar 22;7(12):13464-78. doi: 10.18632/oncotarget.7229. Review.

30.

Tremelimumab for the treatment of malignant mesothelioma.

Guazzelli A, Hussain M, Krstic-Demonacos M, Mutti L.

Expert Opin Biol Ther. 2015;15(12):1819-29. doi: 10.1517/14712598.2015.1116515. Review.

PMID:
26560442
31.

Expression and activity of eIF6 trigger malignant pleural mesothelioma growth in vivo.

Miluzio A, Oliveto S, Pesce E, Mutti L, Murer B, Grosso S, Ricciardi S, Brina D, Biffo S.

Oncotarget. 2015 Nov 10;6(35):37471-85. doi: 10.18632/oncotarget.5462.

32.

The role of microenvironment and immunity in drug response in leukemia.

Bakker E, Qattan M, Mutti L, Demonacos C, Krstic-Demonacos M.

Biochim Biophys Acta. 2016 Mar;1863(3):414-426. doi: 10.1016/j.bbamcr.2015.08.003. Epub 2015 Aug 6. Review.

33.

Expression status of candidate genes in mesothelioma tissues and cell lines.

Melaiu O, Melissari E, Mutti L, Bracci E, De Santi C, Iofrida C, Di Russo M, Cristaudo A, Bonotti A, Cipollini M, Garritano SI, Foddis R, Lucchi M, Pellegrini S, Gemignani F, Landi S.

Mutat Res. 2015 Jan;771:6-12. doi: 10.1016/j.mrfmmm.2014.11.002. Epub 2014 Nov 13.

PMID:
25771974
34.

A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people.

Garritano S, De Santi C, Silvestri R, Melaiu O, Cipollini M, Barone E, Lucchi M, Barale R, Mutti L, Gemignani F, Bonotti A, Foddis R, Cristaudo A, Landi S.

J Thorac Oncol. 2014 Nov;9(11):1662-8. doi: 10.1097/JTO.0000000000000322.

35.

MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.

Melaiu O, Stebbing J, Lombardo Y, Bracci E, Uehara N, Bonotti A, Cristaudo A, Foddis R, Mutti L, Barale R, Gemignani F, Giamas G, Landi S.

PLoS One. 2014 Jan 21;9(1):e85935. doi: 10.1371/journal.pone.0085935. eCollection 2014. Erratum in: PLoS One. 2017 Jun 22;12 (6):e0180317.

36.

Estrogen receptor β activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo.

Manente AG, Valenti D, Pinton G, Jithesh PV, Daga A, Rossi L, Gray SG, O'Byrne KJ, Fennell DA, Vacca RA, Nilsson S, Mutti L, Moro L.

Oncogenesis. 2013 Sep 23;2:e72. doi: 10.1038/oncsis.2013.32.

37.

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.

Calabrò L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D, Di Giacomo AM, Danielli R, Altomonte M, Mutti L, Maio M.

Lancet Oncol. 2013 Oct;14(11):1104-1111. doi: 10.1016/S1470-2045(13)70381-4. Epub 2013 Sep 11.

PMID:
24035405
38.

Negative modulation of mitochondrial oxidative phosphorylation by epigallocatechin-3 gallate leads to growth arrest and apoptosis in human malignant pleural mesothelioma cells.

Valenti D, de Bari L, Manente GA, Rossi L, Mutti L, Moro L, Vacca RA.

Biochim Biophys Acta. 2013 Dec;1832(12):2085-96. doi: 10.1016/j.bbadis.2013.07.014. Epub 2013 Aug 2.

39.

Therapies currently in Phase II trials for malignant pleural mesothelioma.

Pinton G, Manente AG, Tavian D, Moro L, Mutti L.

Expert Opin Investig Drugs. 2013 Oct;22(10):1255-63. doi: 10.1517/13543784.2013.816281. Epub 2013 Jul 2. Review.

PMID:
23815672
40.

BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma.

Busacca S, Chacko AD, Klabatsa A, Arthur K, Sheaff M, Barbone D, Mutti L, Gunasekharan VK, Gorski JJ, El-Tanani M, Broaddus VC, Gaudino G, Fennell DA.

PLoS One. 2013 Jun 7;8(6):e65489. doi: 10.1371/journal.pone.0065489. Print 2013. Erratum in: PLoS One. 2013;8(12). doi:10.1371/annotation/90879c69-ebc5-40b2-9926-4a00e4f9e055. Barbone, Dario [added]; Mutti, Luciano [added].

41.

Preclinical demonstration of synergistic Active Nutrients/Drug (AND) combination as a potential treatment for malignant pleural mesothelioma.

Volta V, Ranzato E, Martinotti S, Gallo S, Russo MV, Mutti L, Biffo S, Burlando B.

PLoS One. 2013;8(3):e58051. doi: 10.1371/journal.pone.0058051. Epub 2013 Mar 6.

42.

Circulating tumor cells as a diagnostic test for malignant pleural mesothelioma.

Pinton G, Manente AG, Moro L, Mutti L.

Expert Opin Med Diagn. 2012 May;6(3):171-3. doi: 10.1517/17530059.2012.676042.

PMID:
23480683
43.

PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1.

Pinton G, Manente AG, Murer B, De Marino E, Mutti L, Moro L.

J Cell Mol Med. 2013 Feb;17(2):233-41. doi: 10.1111/jcmm.12000. Epub 2013 Jan 10.

44.

Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma.

Blayney JK, Ceresoli GL, Castagneto B, O'Brien ME, Hasan B, Sylvester R, Rudd R, Steele J, Busacca S, Porta C, Mutti L, O'Byrne KJ, Scullin P, Gaafar R, Baas P, Van Meerbeeck J, Fennell DA.

Eur J Cancer. 2012 Nov;48(16):2983-92. doi: 10.1016/j.ejca.2012.05.018. Epub 2012 Jun 15.

PMID:
22704893
45.

Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma.

Pinton G, Manente AG, Angeli G, Mutti L, Moro L.

PLoS One. 2012;7(5):e36856. doi: 10.1371/journal.pone.0036856. Epub 2012 May 10.

46.

Epigallocatechin-3-gallate induces mesothelioma cell death via H2 O2 -dependent T-type Ca2+ channel opening.

Ranzato E, Martinotti S, Magnelli V, Murer B, Biffo S, Mutti L, Burlando B.

J Cell Mol Med. 2012 Nov;16(11):2667-78. doi: 10.1111/j.1582-4934.2012.01584.x.

47.

Chemoprevention of asbestos-linked cancers: a systematic review.

Neri M, Ugolini D, Boccia S, Canessa PA, Cesario A, Leoncini G, Mutti L, Bonassi S.

Anticancer Res. 2012 Mar;32(3):1005-13. Review.

PMID:
22399624
48.

Sustained expression of steroid receptor coactivator SRC-2/TIF-2 is associated with better prognosis in malignant pleural mesothelioma.

Jennings CJ, O'Grady A, Cummins R, Murer B, Al-Alawi M, Madden SF, Mutti L, Harvey BJ, Thomas W, Kay EW.

J Thorac Oncol. 2012 Jan;7(1):243-8. doi: 10.1097/JTO.0b013e31822f6544.

49.

Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications.

Calabrò L, Sigalotti L, Fonsatti E, Bertocci E, Di Giacomo AM, Danielli R, Cutaia O, Colizzi F, Covre A, Mutti L, Natali PG, Maio M.

J Cell Physiol. 2011 Oct;226(10):2595-600. doi: 10.1002/jcp.22600.

PMID:
21792917
50.

Estrogen receptor β exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib.

Pinton G, Thomas W, Bellini P, Manente AG, Favoni RE, Harvey BJ, Mutti L, Moro L.

PLoS One. 2010 Nov 29;5(11):e14110. doi: 10.1371/journal.pone.0014110.

Supplemental Content

Support Center